High-Throughput Cell Based Assay for the Identification of Drugs Targeting the NF-kB Signaling Pathway

Tech ID: 02-05

Summary

Researchers at National Jewish Health have developed a microscopy-based visual assay to measure the antigen-receptor activation of an intermediate molecule located upstream of NF-kB

Potential Applications

Identification of compounds as potential agents against inflammatory diseases, immune diseases and cancer

Advantages of Invention

The assay targets Bcl10, a specific intermediate protein of the NF- kB pathway, and it is compatible with epifluorescence/confocal microscopy

State of Development

Using cell lines developed in-house, National Jewish Health scientists have demonstrated that T cell receptor activation of NF-kB involves the dynamic relocalization of the signaling intermediate Bcl10. This protein movement can be visualized by confocal or epifluorescence microscopy using a fluorescent marker (such as GFP) or antibodies.

Patent Status

Issued U.S. Patent #7,169,570

Publication

• Schaefer BC, et. al. Proc Natl Acad Sci U S A. 2004 Jan 27; 101(4):1004-9. Epub 2004 Jan 14. PMID: 14724296

Inventors

Brian Schaefer, PhD, Philippa Marrack, PhD and John Kappler, PhD

Licensing Status - This technology is available for licensing.

 

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org